secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001104659-25-024784
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia secures up to $100M in additional financing from HCR for YUTREPIA commercialization
--------------------------------------------------------------------------------

- $25M funded at closing; $50M contingent on first commercial sale of YUTREPIA after FDA approval for PAH/PH-ILD (no injunction).
- Additional $25M available if YUTREPIA net sales exceed $100M by June 30, 2026, subject to mutual agreement.
- Payments capped at 175% of amounts advanced; minimum IRR rates: 16%/13%/12% for three new tranches.
- CFO: combination of proceeds and successful YUTREPIA launch could lead to profitability without additional capital.
- Proceeds to fund YUTREPIA commercial development, clinical trials, L606 development, and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925024784/0001104659-25-024784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925024784/tm259465d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-024784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer